Title : EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

Pub. Date : 2013 Nov

PMID : 24192124






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EGFR mutation as well as KRAS and ALK rearrangements are important biomarkers in the field owing to potential targeted therapies involved in clinical practice: erlotinib, geftinib, cetuximab and crizotinib. Erlotinib Hydrochloride ALK receptor tyrosine kinase Homo sapiens